Relmada Therapeutics
RLMD
87 hedge funds and large institutions have $45M invested in Relmada Therapeutics in 2023 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 11 increasing their positions, 40 reducing their positions, and 14 closing their positions.
13% more capital invested
Capital invested by funds: $39.7M → $45M (+$5.32M)
3.71% less ownership
Funds ownership: 53.52% → 49.8% (-3.7%)
8% less funds holding
Funds holding: 95 → 87 (-8)
57% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 14
73% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 40
85% less call options, than puts
Call options by funds: $140K | Put options by funds: $914K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$374K |
| 2 |
SSA
Schonfeld Strategic Advisors
New York
|
+$325K |
| 3 |
PCM
Parsons Capital Management
Providence,
Rhode Island
|
+$299K |
| 4 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$297K |
| 5 |
GIM
Guild Investment Management
Los Angeles,
California
|
+$278K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$693K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$462K |
| 3 |
Goldman Sachs
New York
|
-$444K |
| 4 |
Two Sigma Investments
New York
|
-$320K |
| 5 |
Millennium Management
New York
|
-$296K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
101
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| – | -$241 | -98 | Closed |
|
RLMD Hedge Fund Activity: Q3 2023 in Review
87 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Relmada Therapeutics (RLMD) for Q3 2023, worth a combined $45M — up 13% from $39.7M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of RLMD and 6 opened new positions — a net loss of 8 holders — while 40 trimmed existing stakes and 11 added.
The largest buyer was Jacobs Levy Equity Management, opening a new position worth an estimated $374K. The largest seller was Deutsche Bank, cutting an estimated $693K.
- 87 institutional investors held Relmada Therapeutics (RLMD) as of Q3 2023, down from 95 in Q2 2023.
- Funds reported $45M of Relmada Therapeutics stock for Q3 2023, up 13% quarter-over-quarter.
- 6 funds opened new Relmada Therapeutics positions in Q3 2023 and 14 closed out, a net change of -8 holders.
- The largest Relmada Therapeutics buyer in Q3 2023 was Jacobs Levy Equity Management, an estimated $374K added.
- The largest Relmada Therapeutics seller in Q3 2023 was Deutsche Bank, an estimated $693K sold.
Based on aggregated 13F filings for Q3 2023.